Search results
Results from the WOW.Com Content Network
5-Methoxy-7,N,N-trimethyltryptamine (5-MeO-7,N,N-TMT, 5-MeO-7-TMT), is a tryptamine derivative which acts as a partial agonist at the 5-HT 2 serotonin receptors, with an EC 50 of 63.9 nM and an efficacy of 66.2% at 5-HT 2A (vs 5-HT), and weaker activity at 5-HT 2B and 5-HT 2C.
5-Methoxy-2,N,N-trimethyltryptamine (5-MeO-2,N,N-TMT, 5-MeO-TMT) is a psychoactive drug of the tryptamine chemical class which acts as a psychedelic.It was first synthesized by Alexander Shulgin and reported in his book TiHKAL ("Tryptamines i Have Known And Loved").
5-Methoxy-α,N,N-trimethyltryptamine (5-MeO-α,N,N-TMT), also known as α,N,N,O-tetramethylserotonin (α,N,N,O-TMS), is a little-known synthetic substituted tryptamine and the combined derivative of 5-MeO-DMT and α-methyltryptamine (αMT or AMT).
5-MeO-DMT is a potent and fast-acting psychedelic, which is naturally produced by the Sonoran Desert toad as well as some species of plants. Its short duration –from 20 minutes to one hour– is ...
5-Methoxytryptamine (5-MT, 5-MeO-T, or 5-OMe-T), also known as serotonin methyl ether or O-methylserotonin and as mexamine, is a tryptamine derivative closely related to the neurotransmitters serotonin and melatonin. [3]
α,N,O-TMS, or α,N-dimethyl-5-methoxy tryptamine, is a lesser-known psychedelic drug. Its abbreviated nomenclature is derived from its structure, as it is α, N , O -tri methyl serotonin . α, N , O -TMS was first synthesized by Alexander Shulgin .
5,N,N-trimethyltryptamine (5,N,N-TMT; 5-TMT) is a tryptamine derivative that is a psychedelic drug. It was first made in 1958 by Edwin H. P. Young. [1] In animal experiments it was found to be in between DMT and 5-MeO-DMT in potency [2] [3] which would suggest an active dosage for humans in the 20–60 mg range.
NMT is known to act as a potent serotonin 5-HT 2A receptor full agonist (EC 50 Tooltip half-maximal effective concentration = 50.7 nM; E max Tooltip maximal efficacy = 96%). [5] It has been reported to be inactive in activating the β-arrestin pathway of the receptor and hence appears to be a biased agonist of the serotonin 5-HT 2A receptor. [5]